SLRN icon

ACELYRIN

2.13 USD
+0.07
3.40%
At close Feb 14, 4:00 PM EST
After hours
2.11
-0.02
0.94%
1 day
3.40%
5 days
3.40%
1 month
1.43%
3 months
-58.72%
6 months
-47.54%
Year to date
-35.45%
1 year
-72.27%
5 years
-90.94%
10 years
-90.94%
 

About: Acelyrin Inc is a late-stage clinical biopharmaceutical company. It is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of of transformative medicines.

Employees: 130

0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

109% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 11

17% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 36

9% more funds holding

Funds holding: 112 [Q2] → 122 (+10) [Q3]

8% more capital invested

Capital invested by funds: $401M [Q2] → $434M (+$33.8M) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q2] → 3 (+0) [Q3]

3.47% less ownership

Funds ownership: 91.73% [Q2] → 88.26% (-3.47%) [Q3]

43% less call options, than puts

Call options by funds: $154K | Put options by funds: $272K

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$3
41%
upside
Avg. target
$7.33
244%
upside
High target
$13
510%
upside

3 analyst ratings

positive
33%
neutral
67%
negative
0%
Citigroup
Samantha Semenkow
21% 1-year accuracy
3 / 14 met price target
41%upside
$3
Neutral
Maintained
7 Jan 2025
HC Wainwright & Co.
Emily Bodnar
20% 1-year accuracy
31 / 155 met price target
182%upside
$6
Neutral
Maintained
7 Jan 2025
Wells Fargo
Derek Archila
36% 1-year accuracy
13 / 36 met price target
510%upside
$13
Overweight
Maintained
11 Dec 2024

Financial journalist opinion

Based on 6 articles about SLRN published over the past 30 days

Neutral
Business Wire
6 days ago
ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Acelyrin, Inc. (NasdaqGS: SLRN) to Alumis Inc. (NasdaqGS: ALMS). Under the terms of the proposed transaction, shareholders of Acelyrin will receive 0.4274 shares of Alumis common stock for each share of Acelyrin that they own. KSF is seeking to determine whether this consideration and the process that led to i.
ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN
Neutral
PRNewsWire
1 week ago
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.
NEW YORK , Feb. 7, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by ACELYRIN, INC. (NASDAQ: SLRN) and its board of directors concerning the proposed acquisition of the company by Alumis Inc. (NASDAQ: ALMS).
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.
Neutral
Business Wire
1 week ago
SLRN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ACELYRIN, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of ACELYRIN, INC. (NASDAQ: SLRN) to Alumis Inc. for 0.4274 shares of Alumis common stock for each share of ACELYRIN common stock is fair to ACELYRIN shareholders. Halper Sadeh encourages ACELYRIN shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The.
SLRN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ACELYRIN, Inc. Is Fair to Shareholders
Neutral
PRNewsWire
1 week ago
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Acelyrin, Inc. - SLRN
NEW YORK , Feb. 6, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Acelyrin, Inc. (Nasdaq: SLRN ), relating to the proposed merger with Alumis Inc. Under the terms of the agreement, Acelyrin stockholders will receive 0.4274 shares of Alumis common stock per share of common stock owned.
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Acelyrin, Inc. - SLRN
Neutral
Business Wire
1 week ago
Shareholder Alert: Ademi & Fruchter LLP investigates whether ACELYRIN, INC. is obtaining a Fair Price for its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--Ademi & Fruchter LLP is investigating ACELYRIN (Nasdaq: SLRN) for possible breaches of fiduciary duty and other violations of law in its transaction with Alumis. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, ACELYRIN stockholders will receive only 0.4274 shares of Alumis common stock for each share of AC.
Shareholder Alert: Ademi & Fruchter LLP investigates whether ACELYRIN, INC. is obtaining a Fair Price for its Public Shareholders
Neutral
GlobeNewsWire
1 week ago
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
Topline data from Phase 3 ONWARD trials for Alumis' ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout in 2026
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
Negative
Benzinga
1 month ago
Acelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were mostly higher this morning, with the Dow futures gaining around 0.1% on Tuesday.
Acelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Neutral
GlobeNewsWire
1 month ago
ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease
Totality of data observed with subcutaneous lonigutamab in Thyroid Eye Disease (TED) patients demonstrate potential for efficacy in line with standard of care and a more favorable safety profile
ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease
Neutral
GlobeNewsWire
1 month ago
ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab
LOS ANGELES, Jan. 02, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a virtual investor event on Monday, January 6, 2025 at 4:30 PM ET to provide updated Phase 2 data for subcutaneous lonigutamab further supporting its potential for a best-in-class efficacy and safety profile in Thyroid Eye Disease (TED). The event will also feature external clinician perspectives on the continuing unmet needs in TED and disclose the design for the Phase 3 LONGITUDE program, which was developed following a successful End-of-Phase 2 meeting with the FDA to be the most inclusive registrational program to date in TED. To register, click here.
ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab
Neutral
GlobeNewsWire
2 months ago
ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis
Phase 2b/3 trial of izokibep did not meet primary endpoint; secondary endpoints also did not achieve statistical significance
ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis
Charts implemented using Lightweight Charts™